Carl Dieffenbach Ph.D
Director, DAIDS, NIAID
National Institutes of Health, Bethesda, MD
Title:Drug Development for HIV: We have come so far, and we are not yet done
Carl W. Dieffenbach, Ph.D., serves as Director of the Division of AIDS (DAIDS). Dr. Dieffenbach oversees a global HIV/AIDS research portfolio of more than $1 billion and a staff of more than 150 federal employees. He played a key role in restructuring the DAIDS-supported clinical trials research networks and has actively fostered collaboration and partnerships with other federal agencies, international research organizations, foundations, and industry. In 1992, he joined DAIDS as the chief of the preclinical therapeutics group. Upon his appointment, Dr. Dieffenbach spearheaded important research initiatives that accelerated the progress of basic research on HIV pathogenesis and directly resulted in new clinical studies of novel AIDS therapies. In 1996, he was promoted to Director of the DAIDS Basic Sciences Program, where he remained until being selected as the division director in 2008. In 2011, Dr. Dieffenbach received the Distinguished Alumnus Award of the Department of Chemistry and Biochemistry, University of Maryland.
Lawrence Vernetti, Ph.D.
Director of Early Drug Safety University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA